Year 2017 / Volume 109 / Number 6
Original
Matrix metalloproteases expression in different histological types of colorectal polyps

414-420

DOI: 10.17235/reed.2017.4551/2016

Noemi Eiró, Luis O. González, Sandra Cid, Alejandro Andicoechea, Francisco J. Vizoso,

Abstract
Introduction: Colorectal carcinoma (CC) may begin as benign polyps, which may be classified in different histological types with a different risk to develop cancer. Matrix metalloproteases (MMPs) are able to degrade all components in the extracellular matrix and are important tissue-remodeling enzymes and key elements in tumor invasion and metastasis. The aim of this study was to investigate the expression and clinical relevance of MMPs in different histological types of colorectal polyps. Methods: The expression levels of MMP-1, 2, 7, 9, 11, 13 and 14 were analyzed by real-time PCR, Western-blot and immunohistochemistry in 50 patients with different histological types of colorectal polyps, 28 of which developed CC. Results: The results indicate that hyperplastic polyps had the lowest levels of MMP-1 and MMP-7, tubular polyps showed higher levels of both MMP-7 and MMP-14, and tubulovillous adenoma showed higher levels of MMP-1, MMP-7 and MMP-14. Conclusion: MMP expression was decreased in hyperplastic, tubular and tubulovillous adenoma polyps from patients who developed CC. Our findings suggest that MMP expression may be a pathological marker of colorectal polyps and for cancer susceptibility, which may improve strategies for CC prevention based on screening colonoscopy.
Share Button
New comment
Comments
No comments for this article
References
[1]. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300.
[2]. Bujanda L, Cosme A, Gil I, Arenas-Mirave JI. Malignant colorectal polyps. World J Gastroenterol 2010;16(25):3103-11.
[3]. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003;124(2):544-60.
[4]. Levin TR, Zhao W, Conell C, Seeff LC, Manninen DL, Shapiro JA, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 2006;145(12):880-6.
[5]. Markowitz AJ, Winawer SJ. Screening and surveillance for colorectal carcinoma. Hematol Oncol Clin North Am 1997;11(4):579-608.
[6]. Eiro N, Gonzalez L, Gonzalez LO, Andicoechea A, Fernandez-Diaz M, Altadill A, et al. Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer. J Clin Immunol 2012;32(4):848-54.
[7]. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13(5):816-25.
[8]. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009;61(2):177-97.
[9]. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler 1995;376(6):345-55.
[10]. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004;16(5):558-64.
[11]. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18(5):1135-49.
[12]. Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 1999;274(11):6935-45.
[13]. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001;114(Pt 1):111-118.
[14]. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161-74.
[15]. Turk V, Kos J, Turk B. Cysteine cathepsins (proteases)--on the main stage of cancer? Cancer Cell 2004;5(5):409-10.
[16]. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001;3(6):459-68.
[17]. Gonzalez L, Eiro N, Gonzalez LO, Andicoechea A, Barbon E, Garcia-Muniz JL, et al. Effect of the expression of matrix metalloproteases and their tissue inhibitors on survival of patients with resectable colorectal cancer. Dig Dis Sci 2012;57(8):2063-71.
[18]. Eiro N, Gonzalez-Reyes S, Gonzalez L, Gonzalez LO, Altadill A, Andicoechea A, et al. Duodenal Expression of Toll-Like Receptors and Interleukins Are Increased in Both Children and Adult Celiac Patients. Dig Dis Sci 2012.
[19]. Shi SR, Liu C, Balgley BM, Lee C, Taylor CR. Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J Histochem Cytochem 2006;54(6):739-43.
[20]. Liljegren A, Lindblom A, Rotstein S, Nilsson B, Rubio C, Jaramillo E. Prevalence and incidence of hyperplastic polyps and adenomas in familial colorectal cancer: correlation between the two types of colon polyps. Gut 2003;52(8):1140-7.
[21]. Lim HK, Lee KH, Kim SY, Kim KJ, Kim B, Lee H, et al. Does the amount of tagged stool and fluid significantly affect the radiation exposure in low-dose CT colonography performed with an automatic exposure control? Eur Radiol 2011;21(2):345-52.
[22]. Omata F, Deshpande G, Tokuda Y, Takahashi O, Ohde S, Carr-Locke DL, et al. Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis. J Gastroenterol 2010;45(8):885-95.
[23]. Torlakovic E, Snover DC. Sessile serrated adenoma: a brief history and current status. Crit Rev Oncog 2006;12(1-2):27-39.
[24]. Jass JR. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol 2005;2(8):398-405.
[25]. Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 2005;129(6):1991-2008.
[26]. Pesta M, Topolcan O, Holubec L, Jr., Rupert K, Cerna M, Holubec LS, et al. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 2007;27(4A):1863-7.
[27]. Asano T, Tada M, Cheng S, Takemoto N, Kuramae T, Abe M, et al. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res 2008;146(1):32-42.
[28]. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2(4):461-2.
[29]. Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006;12(4):1184-91.
[30]. Jensen SA, Vainer B, Bartels A, Brunner N, Sorensen JB. Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells--associations with histopathology and patients outcome. Eur J Cancer 2010;46(18):3233-42.
[31]. Chu D, Zhao Z, Zhou Y, Li Y, Li J, Zheng J, et al. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Ann Surg Oncol 2012;19(1):318-25.
[32]. Akishima-Fukasawa Y, Ishikawa Y, Akasaka Y, Uzuki M, Inomata N, Yokoo T, et al. Histopathological predictors of regional lymph node metastasis at the invasive front in early colorectal cancer. Histopathology 2011;59(3):470-81.
[33]. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7(10):800-8.
[34]. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007;26(3-4):717-24.
[35]. Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008;19(1):52-60.
[36]. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21(14):2245-52.
[37]. Sinnamon MJ, Carter KJ, Fingleton B, Matrisian LM. Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse. Int J Exp Pathol 2008;89(6):466-75.
[38]. Garg P, Sarma D, Jeppsson S, Patel NR, Gewirtz AT, Merlin D, et al. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res 2010;70(2):792-801.
[39]. Jeffery N, McLean MH, El-Omar EM, Murray GI. The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. Histopathology 2009;54(7):820-8.
Related articles

Digestive Diseases Image

Spontaneous regression of a rectal cancer

DOI: 10.17235/reed.2023.9486/2023

Letter

Vaginal lesion as first manifestation of colorectal disease

DOI: 10.17235/reed.2022.9270/2022

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Original

Can we optimize CEA as a response marker in rectal cancer?

DOI: 10.17235/reed.2020.7321/2020

Review

New non-invasive biomarkers for colorectal cancer screening

DOI: 10.17235/reed.2020.7233/2020

Letter

Medullary colorectal carcinoma. Do we really know it?

DOI: 10.17235/reed.2020.6728/2019

Letter

The rectosigmoid junction: are limits important?

DOI: 10.17235/reed.2019.5983/2018

Editorial

Colorectal cancer screening and survival

DOI: 10.17235/reed.2018.5870/2018

Editorial

The right colon challenge

DOI: 10.17235/reed.2018.5544/2018

Letter to the Editor

Neuroendocrine tumors of the pancreas: keys issues in dealing with heterogeneity

DOI: 10.17235/reed.2017.4997/2017

Letter to the Editor

Pancreatic neuroendocrine tumors. Prognostic factors

DOI: 10.17235/reed.2017.5109/2017

Editorial

Pancreas neuroendocrine tumors - not so rare or benign

DOI: 10.17235/reed.2016.4672/2016

Letter to the Editor

Liver metastasis from colorectal cancer 12 years after liver transplantation

DOI: 10.17235/reed.2017.4507/2016

Review

Serrated lesions and serrated polyposis syndrome

DOI: 10.17235/reed.2017.4065/2015

Letter to the Editor

Endobronchial metastases of colorectal cancer

DOI: 10.17235/reed.2016.4080/2015

Citation tools
Eiró N, González L, Cid S, Andicoechea A, Vizoso F. Matrix metalloproteases expression in different histological types of colorectal polyps. 4551/2016


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1115 visits.
This article has been downloaded 155 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 19/07/2016

Accepted: 14/01/2017

Online First: 05/04/2017

Published: 01/06/2017

Article revision time: 141 days

Article Online First time: 260 days

Article editing time: 317 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology